According to DataM Intelligence, the  global point-of-care (POC) lipid test market  reached US$ 0.68 billion in 2023, with a rise to US$ 0.72 billion in 2024, and is expected to reach US$ 1.23 billion by 2033, growing at a CAGR of 6.8% from  2025 to 2033. This dynamic market is driven by a growing focus on preventive healthcare, decentralized diagnostics, and patient-centered care, enabling rapid lipid testing to manage cardiovascular risks outside traditional labs. POC lipid tests deliver immediate results, supporting timely interventions for cholesterol management and heart disease prevention.

Advancements in portable analyzers, smartphone-enabled devices, and digital connectivity enhance test accuracy and integration with healthcare systems. The rise of pharmacy-based services, home monitoring, and telehealth, combined with demand in emerging markets, fuels accessibility and long-term market growth.

For a detailed sample PDF brochure of the report, use a corporate email ID for a quick response: Download Sample PDF.

Market Segmentation

• By Product Type: Instruments, Consumables

• By Disease Indication: Hyperlipidemia, Hypercholesterolaemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, Others

• By Application: Research and Development, Diagnostics, Biotechnological Product Manufacturing, Agriculture, Others

• By End-User: Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations (CDMOs), Diagnostic Laboratories & Clinical Research Centers, Others

• By Region: North America, Europe, Asia-Pacific, South America, Middle East and Africa

Regional Insights

• North America leads the market, driven by advanced healthcare infrastructure, widespread diagnostic facilities, and strong adoption of preventive care in the U.S. and Canada.

• Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular and metabolic disorders, expanding healthcare access, and digital health integration in countries like China, India, Japan, and South Korea.

• Europe benefits from robust healthcare systems and regulatory support, with growth in pharmacy-based and community screening programs.

• South America, Middle East, and Africa show potential due to increasing healthcare investments and awareness of cardiovascular risks.

Key Market Drivers

• Rising global cardiovascular disease burden, necessitating early lipid screening for heart attack and stroke prevention.

• Demand for rapid, accessible diagnostics in primary care, pharmacies, and community settings, enabling same-visit interventions.

• Technological advancements in portable analyzers, connectivity, and multiplexing, improving accuracy and usability.

• Growth in telehealth, home-based monitoring, and emerging market healthcare programs, expanding POC lipid test adoption.

Leading Market Players

Key companies in the POC lipid test market include:

• Abbott

• F. Hoffmann-La Roche Ltd

• Siemens Healthcare Private Limited (Siemens Healthineers AG)

• SD Biosensor, INC.

• ACON Laboratories, Inc.

• PTS Diagnostics

• Woodley Equipment Company Ltd

These players focus on innovation in device design, regulatory approvals, and expanding distribution in clinical and consumer channels.

Recent Industry Developments

• Abbott Laboratories (June 2025): Launched an AI-integrated POC lipid test device approved for retail pharmacies, enhancing accuracy and providing real-time lipid management insights.

• Health Network Expansion (August 2025): Implemented rapid POC lipid screening in telehealth mobile units, enabling on-the-spot cholesterol monitoring in remote and underserved areas.

• Roche Diagnostics (March 2025): Introduced an updated Cobas b101 POC analyzer with improved throughput and faster turnaround for triglyceride and cholesterol testing in clinical settings.

• Siemens Healthineers (April 2025): Received CE marking for its newly developed POC lipid test cartridge compatible with handheld analyzers, expanding European market access.

Conclusion

The POC lipid test market is set for robust growth through 2033, driven by the need for rapid, accessible cardiovascular risk management. By enabling immediate lipid testing in diverse settings, these solutions enhance preventive care and patient outcomes. With North America’s dominance, Asia-Pacific’s rapid expansion, and continuous technological innovation, POC lipid tests will play a critical role in global healthcare, addressing rising cardiovascular challenges effectively.